Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
The company operates through three segments: BioScience, Medication Delivery, and Renal. Patients and providers rely on Baxter for lifesaving renal and medical products, including intravenous (IV) solutions, systems and administrative sets, IV infusion parenteral nutrition, perioperative care, pharmacy devices and software, acute renal care, and home and in-center dialysis.
Closing share price
|FY, 2011||FY, 2012||FY, 2013||FY, 2014||FY, 2015||FY, 2016|
|$15.3 b||$16.7 b||$10 b||$10.2 b|
Revenue growth, %
|$7.6 b||$8.2 b||$4.1 b|
|$2.5 b||$2.4 b||$449 m|
|$2 b||$2.5 b||$968 m||$5 b|
Operating cash flow
|($537 m)||$192 m||($712 m)|